The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1720
    
   			ISSUE 1720
January 20, 2025
                			
                		 Issue 1720
                		- Valeda Light Delivery System for Age-Related Macular Degeneration
 - Emrosi — Low-Dose, Biphasic Oral Minocycline for Rosacea
 - Dupilumab (Dupixent) for COPD
 - Seladelpar (Livdelzi) for Primary Biliary Cholangitis
 - Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
 - Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				Valeda Light Delivery System for Age-Related Macular Degeneration
January 20, 2025 (Issue: 1720)
				The FDA has authorized use of the Valeda Light
Delivery System (LumiThera), a multiwavelength
photobiomodulation (PBM) device, to improve visual
acuity in patients with dry age-related macular
degeneration (AMD) who have best-corrected...more
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				